Enteric Disease Testing Market By Product Type (Reagents and Consumables, Equipment), By Technique (Molecular Diagnostics, Immunodiagnostics), By Disease Type (Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease), By End User (Hosp

Enteric Disease Testing Market By Product Type (Reagents and Consumables, Equipment), By Technique (Molecular Diagnostics, Immunodiagnostics), By Disease Type (Bacterial Enteric Disease, Viral Enteric Disease, Parasitic Enteric Disease), By End User (Hospital Laboratories, Pharmaceutical and Biotechnology Companies, Academic and Research Institutes): Global Opportunity Analysis and Industry Forecast, 2023-2032

The enteric disease testing market was valued at $3,870.60 million in 2022 and is estimated to reach $5,323.60 million by 2032, exhibiting a CAGR of 3.3% from 2023 to 2032. Enteric diseases are infections caused by various microorganisms, including bacteria, viruses, and parasites, that affect the gastrointestinal tract (also known as the enteric or digestive system). These diseases are typically spread through contaminated food or water, poor sanitation, or inadequate hygiene practices. Enteric diseases are tested using molecular diagnostics techniques and immunodiagnostic techniques. Testing for enteric diseases is important for treatment, and prevention of the spread of infectious diseases. Various reagents, consumables, and equipment are used in the testing of enteric diseases.

Major factors driving the growth of the enteric disease testing market include rise in technological advancement in testing reagents and equipment of enteric disease, increase in initiative taken by governments in developing countries to reduce the burden of infectious enteric diseases, peptic ulcer and surge in prevalence of enteric diseases such as E. coli infection, amoebiasis, giardiasis, H. pylori infection, shigella and salmonella infection. For instance, according to Centers for Disease Control and Prevention (CDC) 2023, campylobacter infection affects 1.5 million U.S. residents every year.

However, the high cost of equipment and high cost associated with molecular diagnostic assay are expected to hamper the enteric disease testing market growth. On the contrary, unmet medical demands in developing countries and lucrative opportunities in emerging economies are expected to create immense opportunities for enteric disease testing product manufacturers in the future.

Furthermore, the healthcare business is projected to witness growth, owing to a rise in the use of enteric disease testing for research and development activities, high demand for enteric disease testing kits, and high incidence rate of enteric diseases. In addition, rise in discovery & development of effective enteric disease testing kits & equipment and increase in awareness regarding diagnosis of enteric disease drive the growth of the enteric disease testing market in developing countries such as India and China. This is anticipated to offer remunerative opportunities for key players to invest in the market during the forecast period.

The enteric disease testing market is segmented into product type, technique, disease type, end user, and region. On the basis of product type, the market is classified into reagents and consumables, and equipment. On the basis of technique, the market is bifurcated into molecular diagnostics, and immunodiagnostics. On the basis of disease type, the market is divided into bacterial enteric disease, viral enteric disease, and parasitic enteric disease. On the basis of end user, it is segregated into hospital laboratories, pharmaceutical and biotechnology companies, academic and research institutes. 

Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

Major players profiled in the report include Abbott Laboratories, Becton Dickinson & Company, Biomerica, Inc., Biomerieux SA, Bio-Rad Laboratories, Inc., Coris Bioconcept, Diasorin S.p.A., Meridian Bioscience, Inc, Quest Diagnostics, and Trinity Biotech.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the enteric disease testing market analysis from 2022 to 2032 to identify the prevailing enteric disease testing market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the enteric disease testing market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global enteric disease testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product Type

Reagents and Consumables
Equipment

By Technique

Molecular Diagnostics
Immunodiagnostics

By Disease Type

Bacterial Enteric Disease
Viral Enteric Disease
Parasitic Enteric Disease

By End User

Academic and Research Institutes
Hospital Laboratories
Pharmaceutical and Biotechnology Companies

By Region

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Biomerica, Inc.
Diasorin S.p.A.
Meridian Bioscience Inc.
Coris BioConcept
Abbott Laboratories
Biomerieux SA
Bio-Rad Laboratories, Inc. 
Quest Diagnostics Inc.
Becton Dickinson & Company
Trinity Biotech

Please Note: It will take 7-10 business days to complete the report upon order confirmation.